Foresite Capital Management IV’s Nurix Therapeutics NRIX Stock Holding History

Foresite Capital Management IV’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-677,143	Closed	-$8.58M	–	9
2022 Q2	$8.58M	Sell	677,143 -353,655	-34%	-$4.01M	2.31%	6
2022 Q1	$14.4M	Sell	1,030,798 -175,000	-15%	-$3.11M	4.04%	7
2021 Q4	$34.9M	Hold	1,205,798	–	–	7.18%	6
2021 Q3	$36.1M	Hold	1,205,798	–	–	5.32%	6
2021 Q2	$32M	Sell	1,205,798 -32,658	-3%	-$959K	4.32%	7
2021 Q1	$38.5M	Sell	1,238,456 -1,109,348	-47%	-$42M	4.61%	8
2020 Q4	$77.2M	Sell	2,347,804 -210	-0%	-$6.96K	8.39%	5
2020 Q3	$82M	Buy	+2,348,014	New	+$59.2M	18.48%	2

Other funds holding NRIX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Foresite Capital Management IV's NRIX Position: Q3 2022 in Review

Foresite Capital Management IV sold out of Nurix Therapeutics (NRIX) in Q3 2022, closing a stake of 677,143 shares — an estimated $8.58M sold.

Foresite Capital Management IV first reported a position in NRIX in Q3 2020 and held it in 8 quarters. The position peaked at $82M in Q3 2020. 118 funds tracked by Wall St. Rank hold NRIX as of Q3 2022.

Foresite Capital Management IV reported no remaining Nurix Therapeutics position as of Q3 2022 after selling out during the quarter.
Foresite Capital Management IV sold 677,143 Nurix Therapeutics shares in Q3 2022, an estimated $8.58M.
Foresite Capital Management IV first reported a position in Nurix Therapeutics in Q3 2020 and held it in 8 quarters.
Foresite Capital Management IV's Nurix Therapeutics position peaked at $82M in Q3 2020.
118 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2022.

Based on Foresite Capital Management IV's 13F filing for Q3 2022, filed 14 Nov 2022.